47
BioNTech: annual report to US Securities and Exchange Commission: > "We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the US, UK & EU or other countries ..."
posted ago by penisse ago by penisse +47 / -0

BioNTech: annual report to US Securities and Exchange Commission - submitted 30/03/2022 - The Subjunctive Show:

"We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the US, UK & EU or other countries ..."

„If we discover safety issues with (…) our COVID-19 vaccine, (…) approved products could lose their approval or sales could be suspended, we could be subject to product liability claims, our business and reputation could be materially harmed.“

https://investors.biontech.de/node/11931/html

Screen capture: https://files.catbox.moe/2qwimm.png

6 comments
6 comments share save hide report block hide replies